← Leaderboards
Steven E Shoelson
Joslin Diabetes Center
$31,318,982
Attributed
$31,318,982
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$31,318,982 · 18
By mechanism
R01$15,296,375 · 8
U01$7,781,890 · 1
P30$2,934,869 · 3
R37$2,740,774 · 1
P50$2,073,911 · 1
RC4$399,109 · 1
Top collaborators
No co-investigators on record.
Most similar at Joslin Diabetes Center
Same institution · by research overlap
- Andisheh Abedini$153,714
Others in their field
Top investigators on “Obesity”
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
ObesityMetabolicDiabetes MellitusLinkInflammationLiverInsulin ResistanceFatty Acid Glycerol EstersTissuesMediatingMetabolic SyndromeMuscleCardiovascular DiseasesInflammatorySitePathway InteractionsLipidsDietCytokineGlucoseInsulinPathogenesisFastingPrograms
Grant awards (82)
Feeding Drives HSF1 Transcriptional Programs Required for Global Protein Synthesis$380,250
R01 · FY2021 · DK · contact PI
Feeding Drives HSF1 Transcriptional Programs Required for Global Protein Synthesis$422,500
R01 · FY2020 · DK · contact PI
Feeding Drives HSF1 Transcriptional Programs Required for Global Protein Synthesis$380,250
R01 · FY2020 · DK · contact PI
Intrinsic anti-inflammatory actions of AMPK activation rendered through a novel immunometabolic AMPK-mTOR-NFkB Pathway$413,750
R01 · FY2019 · HL · contact PI
Feeding Drives HSF1 Transcriptional Programs Required for Global Protein Synthesis$379,688
R01 · FY2019 · DK · contact PI
P&F Program$369,997
P30 · FY2019 · DK · contact PI
Intrinsic anti-inflammatory actions of AMPK activation rendered through a novel immunometabolic AMPK-mTOR-NFkB Pathway$413,750
R01 · FY2018 · HL · contact PI
Xanthine oxidase inhibition raises intracellular purines to activate AMPK, improve glucose control and decrease fatty liver and atherosclerosis in type 2 diabetes$413,750
R01 · FY2018 · DK · contact PI
Feeding Drives HSF1 Transcriptional Programs Required for Global Protein Synthesis$378,001
R01 · FY2018 · DK · contact PI
P&F Program$368,354
P30 · FY2018 · DK · contact PI
Intrinsic anti-inflammatory actions of AMPK activation rendered through a novel immunometabolic AMPK-mTOR-NFkB Pathway$413,750
R01 · FY2017 · HL · contact PI
Xanthine oxidase inhibition raises intracellular purines to activate AMPK, improve glucose control and decrease fatty liver and atherosclerosis in type 2 diabetes$413,750
R01 · FY2017 · DK · contact PI
P&F Program$365,613
P30 · FY2017 · DK · contact PI
Xanthine oxidase inhibition raises intracellular purines to activate AMPK, improve glucose control and decrease fatty liver and atherosclerosis in type 2 diabetes$413,750
R01 · FY2016 · DK · contact PI
Intrinsic anti-inflammatory actions of AMPK activation rendered through a novel immunometabolic AMPK-mTOR-NFkB Pathway$413,750
R01 · FY2016 · HL · contact PI
Targeting Neutrophils and Leukotrienes to Treat Type 2 Diabetes$351,688
R01 · FY2016 · DK · contact PI
Pilot and Feasibility Program$278,445
P30 · FY2016 · DK · contact PI
Targeting Neutrophils and Leukotrienes to Treat Type 2 Diabetes$351,688
R01 · FY2015 · DK · contact PI
Pilot and Feasibility Program$261,747
P30 · FY2015 · DK · contact PI
Targeting Neutrophils and Leukotrienes to Treat Type 2 Diabetes$352,219
R01 · FY2014 · DK · contact PI
Pilot and Feasibility Program$278,445
P30 · FY2014 · DK · contact PI
Pilot and Feasibility Program$260,728
P30 · FY2013 · DK · contact PI
NF-KB, Inflammation and Vascular Remodeling$447,291
P50 · FY2012 · HL · contact PI
Pilot and Feasibility Program$429,833
P30 · FY2012 · DK · contact PI
NF-KB, Inflammation and Vascular Remodeling$276,765
P50 · FY2011 · HL · contact PI
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate$1,500,000
U01 · FY2010 · DK · contact PI
Mediators and Modifiers of NF-kappaB in Insulin Resistance$459,537
R37 · FY2010 · DK · contact PI
Mechanism-Based Biomarkers for Glucose-Lowering in TINSAL-T2D$399,109
RC4 · FY2010 · DK · contact PI
TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM$295,213
R01 · FY2010 · DK · contact PI
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate$159,909
U01 · FY2010 · DK · contact PI
Mediators and Modifiers of NF-kappaB in Insulin Resistance$42,201
R37 · FY2010 · DK · contact PI
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate$1,456,500
U01 · FY2009 · DK · contact PI
Mediators and Modifiers of NF-kappaB in Insulin Resistance$459,537
R37 · FY2009 · DK · contact PI
EFFECTS OF IKKB and NFkB IN INSULIN RESISTANCE$362,489
R01 · FY2009 · DK · contact PI
TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM$298,194
R01 · FY2009 · DK · contact PI
TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM$40,114
R01 · FY2009 · DK · contact PI
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate$1,582,740
U01 · FY2008 · DK · contact PI
MEDIATORS AND MODIFIERS OF NF-kappaB IN INSULIN RESISTANCE$448,123
R37 · FY2008 · DK · contact PI
NF-KB, Inflammation and Vascular Remodeling$411,621
P50 · FY2008 · HL · contact PI
EFFECTS OF IKKB and NFkB IN INSULIN RESISTANCE$362,489
R01 · FY2008 · DK · contact PI
Ser/Thr Phosphorylation in Insulin Resistance$343,439
R01 · FY2008 · DK · contact PI
TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM$292,230
R01 · FY2008 · DK · contact PI
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate$1,456,501
U01 · FY2007 · DK · contact PI
NF-KB, Inflammation and Vascular Remodeling$523,234
P50 · FY2007 · HL · contact PI
MEDIATORS AND MODIFIERS OF NF-kappaB IN INSULIN RESISTANCE$444,596
R37 · FY2007 · DK · contact PI
EFFECTS OF IKKB and NFkB IN INSULIN RESISTANCE$369,886
R01 · FY2007 · DK · contact PI
Ser/Thr Phosphorylation in Insulin Resistance$350,448
R01 · FY2007 · DK · contact PI
TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM$298,194
R01 · FY2007 · DK · contact PI
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate$126,240
U01 · FY2007 · DK · contact PI
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate$1,500,000
U01 · FY2006 · DK · contact PI
MEDIATORS AND MODIFIERS OF NF-kB IN INSULIN RESISTANCE$444,538
R37 · FY2006 · DK · contact PI
NF-KB, Inflammation and Vascular Remodeling$415,000
P50 · FY2006 · HL · contact PI
EFFECTS OF IKKB and NFkB IN INSULIN RESISTANCE$380,933
R01 · FY2006 · DK · contact PI
Ser/Thr Phosphorylation in Insulin Resistance$360,914
R01 · FY2006 · DK · contact PI
TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM$307,100
R01 · FY2006 · DK · contact PI
EFFECT OF SALICYLATE ON GLUCOSE METABOLISM IN INSULIN RESISTANCE STATES$10,055
M01 · FY2006 · RR · contact PI
MEDIATORS AND MODIFIERS OF NF-kB IN INSULIN RESISTANCE$442,242
R37 · FY2005 · DK
EFFECTS OF IKKB and NFkB IN INSULIN RESISTANCE$390,100
R01 · FY2005 · DK
Ser/Thr Phosphorylation in Insulin Resistance$369,600
R01 · FY2005 · DK
EFFECT OF SALICYLATE ON GLUCOSE METABOLISM IN INSULIN RESISTANCE STATES$22,298
M01 · FY2005 · RR
EFFECT OF SALICYLATE ON GLUCOSE METABOLISM IN INSULIN RESISTANT STATES$16,522
M01 · FY2005 · RR
IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL$416,250
R01 · FY2004 · DK
Ser/Thr Phosphorylation in Insulin Resistance$369,600
R01 · FY2004 · DK
POTENTIAL CAUSE &MOLECULAR TARGET OF INSULIN RESISTANC$318,395
R01 · FY2004 · DK
Salicylate on Glucose Metabolism in Insulin Resistant St$30,235
M01 · FY2004 · RR
Effect of Salicylate on Glucose Metabolism in Insulin Resistance States$12,944
M01 · FY2004 · RR
IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL$416,250
R01 · FY2003 · DK
POTENTIAL CAUSE &MOLECULAR TARGET OF INSULIN RESISTANC$309,121
R01 · FY2003 · DK
IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL$416,250
R01 · FY2002 · DK
STRUCTURE OF IRS PROTEINS IN INSULIN RESISTANCE$313,249
R01 · FY2002 · DK
POTENTIAL CAUSE &MOLECULAR TARGET OF INSULIN RESISTANC$300,116
R01 · FY2002 · DK
IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL$416,250
R01 · FY2001 · DK
STRUCTURE OF IRS PROTEINS IN INSULIN RESISTANCE$304,126
R01 · FY2001 · DK
POTENTIAL CAUSE &MOLECULAR TARGET OF INSULIN RESISTANC$291,375
R01 · FY2001 · DK
CORE--PEPTIDE BIOCHEMISTRY FACILITY$123,636
P30 · FY2001 · DK
CORE--PEPTIDE BIOCHEMISTRY FACILITY$0
P30 · FY2001 · DK
CORE--PEPTIDE BIOCHEMISTRY FACILITY$0
P30 · FY2001 · DK
CORE--PEPTIDE BIOCHEMISTRY FACILITY$0
P30 · FY2001 · DK
CORE--PEPTIDE BIOCHEMISTRY FACILITY$0
P30 · FY2001 · DK
IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL$416,250
R01 · FY2000 · DK
STRUCTURE OF IRS PROTEINS IN INSULIN RESISTANCE$295,266
R01 · FY2000 · DK
CORE--PEPTIDE BIOCHEMISTRY FACILITY$198,071
P30 · FY2000 · DK